Bristol-Myers Squibb Co.

Industry: Major Drugs

Fortune Rank: 114

Bristol-Myers Squibb Company is a global producer and distributor of a variety of pharmaceuticals and related healthcare products. For the six months ended 06/30/05, net sales fell less than 1% to $9.4M. Net income from cont. ops. rose 3% to $1.5M. Revenues reflect lower sales from the pharmaceuticals division. Net income reflects decreased litigation charges, lower provision for restructuring and decreased provision for income taxes.

Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceuticals and other healthcare-related products. The Company operates in three segments: Pharmaceuticals, Nutritionals and Other Healthcare. The Pharmaceuticals segment is made up of the global pharmaceutical and international (excluding Japan) consumer medicines business. The Nutritionals segment consists of Mead Johnson Nutritionals (Mead Johnson), primarily an infant formula and children's nutritionals business. The Other Healthcare segment consists of ConvaTec, Medical Imaging and Consumer Medicines (North America and Japan) businesses. In December 2004, the Company committed to a plan to sell its Oncology Therapeutics Network (OTN) business and entered into a definitive agreement with One Equity Partners LLC. In January 2005, the Company announced its intent to divest its United States and Canadian Consumer Medicines business.

Bristol-Myers Squibb Co.

Bristol-Myers Squibb Co. is a Fortune 500 company. In 2010 Bristol-Myers Squibb Co. was ranked number 114 on the Fortune 500 list, making it the 114th largest company in the United States when judged by revenue.

Bristol-Myers Squibb Co. achieved revenue of $21,634.00 million in 2010 and earned a profit of $10,612.00 million.

Bristol-Myers Squibb Co.' rank improves

The company ranking improved in 2010, moving up the Fortune 500 list to 114th compared to 120th in 2009. This was based on its 2009 revenue of $21,366 million (a change of 0 million compared to 2010) and profits of $5,247 million (a change of $5 million compared to 2009).

Another point of view

To many investors, profits are more important than the revenue a company earns. If the Fortune 500 was ranked by profits instead of revenue then Bristol-Myers Squibb Co. would be ranked 13th rather than 114th due to its profits of $10,612 in 2010.

Bristol-Myers Squibb Co. Revenue* Profit* Fortune Ranking

* US$ Million

USPages Latest Business News At A Glance Business Shortcuts